Article
Whole-exome sequencing reanalysis at 12 months boosts diagnosis and is cost-effective when applied early in Mendelian disorders.
Genetics in medicine : official journal of the American College of Medical Genetics - 1 Dec 2018
Ewans Lisa J, Schofield Deborah, Shrestha Rupendra, Zhu Ying, Gayevskiy Velimir, Ying Kevin, Walsh Corrina, Lee Eric, Kirk Edwin P, Colley Alison, Ellaway Carolyn, Turner Anne, Mowat David, Worgan Lisa, Freckmann Mary-Louise, Lipke Michelle, Sachdev Rani, Miller David, Field Michael, Dinger Marcel E, Buckley Michael F, Cowley Mark J, Roscioli Tony
Abstract excerpt
PURPOSE: Whole-exome sequencing (WES) has revolutionized Mendelian diagnostics, however, there is no consensus on the timing of data review in undiagnosed individuals and only preliminary data on the cost-effectiveness of this technology. We aimed to assess the utility of WES data reanalysis for diagnosis in Mendelian disorders and to analyze the cost-effectiveness of this technology compared with a traditional...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
